Document is current
Any future updates will be listed below
-
Authors
Parvin Nejad, Shouka
Lecce, Monica
Mirani, Bahram
Machado Siqueira, Nataly
Mirzaei, Zahra
Santerre, J. Paul
Davies, John E.
Simmons, Craig A. http://orcid.org/0000-0001-7729-1772
-
Funding
Funding for this research was provided by:
Canadian Institute of Health Research/National Sciences and Engineering Research Council Collaborative Health Research Project (CPG-151962/CHRPJ/CHRPJ 508364-17)
Ted Rogers Centre for Heart Research Translational Biology and Engineering Program (Seed Funding)
- License Information
-
More Information
Article History
Received: 30 October 2022
Accepted: 29 March 2023
First Online: 19 April 2023
Declarations
:
: BMMSCs were provided under a material transfer agreement with the Texas A&M Health Science Centre College of Medicine Institute for Regenerative Medicine at Scott & White. hUCPVCs were provided in-kind to the authors by Tissue Regeneration Therapeutics. Ethics approval and consent to participate for procurement of the cells were obtained by the providers of the cells in adherence with the Declaration of Helsinki.
: Not applicable.
: Dr. John E. Davies is the founding President and CEO of Tissue Regeneration Therapeutics, Inc. (Toronto, ON) who provided the human umbilical cord perivascular cells used in this study. The other authors declare no conflicts of interest.
